In FY 2014 the Ansell sexual wellbeing division sold $213M of product. Market research (available from Starpharma) indicates good (80%) market acceptance of the coated condoms. In answer to your question I do not know!
The Ansell figures for Australia are not in their board report, just the global sales. If we assumed 20% Vivagel penetration (pun not intended) then that would be about $40M of which the minimum double digit royalty figure would give Starpharma $4M per annum. If the penetration is as per the market research then one could assume 4 times this.
Ansell has 11.2% of the global condom market. Others (including Yokamoto 9.2%).
But if Vivagel takes off, I would expect the big players will be calling.
AGM attendance, page-19
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
-0.005(4.76%) |
Mkt cap ! $41.23M | |||
| Open | High | Low | Value | Volume |
| 9.8¢ | 10.5¢ | 9.8¢ | $32.14K | 310.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 70702 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 29081 | 3 |
View Market Depth
| Last trade - 12.27pm 15/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |